Improving antibody therapy for chronic lymphocytic leukemia using NOD2 activation
Novel enhancement of antibody therapy through NOD2 activation
This study is looking at how a special receptor in immune cells can help make antibody treatments work better for people with chronic lymphocytic leukemia (CLL) by boosting the immune system's ability to fight cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10781018 on NIH RePORTER |
What this research studies
This research investigates how activating a specific receptor called NOD2 in immune cells can enhance the effectiveness of antibody therapies for chronic lymphocytic leukemia (CLL). The study focuses on understanding the role of monocytes and macrophages, which are crucial for the immune response, and how they can be manipulated to better attack cancer cells. By using NOD2 agonists, the researchers aim to improve the immune response against CLL, potentially leading to better treatment outcomes for patients. The approach involves laboratory experiments that analyze the changes in immune cell behavior and their interactions with cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with chronic lymphocytic leukemia who are undergoing or considering antibody-based therapies.
Not a fit: Patients with other types of cancers or those not receiving antibody therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective antibody therapies for patients with chronic lymphocytic leukemia, improving their treatment outcomes.
How similar studies have performed: Previous research has shown promising results with similar approaches in enhancing immune responses against cancer, indicating potential for success in this study.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Tridandapani, Susheela — Ohio State University
- Study coordinator: Tridandapani, Susheela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.